Quarterly report pursuant to Section 13 or 15(d)

Acquisitions, Investments and Licenses - Equity and Cost Method Investments Narrative (Details)

v3.8.0.1
Acquisitions, Investments and Licenses - Equity and Cost Method Investments Narrative (Details)
$ in Millions
9 Months Ended
Sep. 30, 2017
USD ($)
Schedule of Equity Method Investments [Line Items]  
Total assets of equity method investees $ 415.4
Total (liabilities) of equity method investees (203.2)
Net (losses) of equity method investees (106.1)
Market value $ 67.4
Pharmsynthez  
Schedule of Equity Method Investments [Line Items]  
Ownership percentage, equity method 9.00%
Cocrystal  
Schedule of Equity Method Investments [Line Items]  
Ownership percentage, equity method 9.00%
Sevion  
Schedule of Equity Method Investments [Line Items]  
Ownership percentage, equity method 31.00%
Non-Invasive Monitoring Systems, Inc.  
Schedule of Equity Method Investments [Line Items]  
Ownership percentage, equity method 1.00%
Neovasc  
Schedule of Equity Method Investments [Line Items]  
Ownership percentage, equity method 4.00%
VBI Vaccines Inc  
Schedule of Equity Method Investments [Line Items]  
Ownership percentage, equity method 15.00%
InCellDx, Inc  
Schedule of Equity Method Investments [Line Items]  
Ownership percentage, equity method 28.00%
BioCardia, Inc.  
Schedule of Equity Method Investments [Line Items]  
Ownership percentage, equity method 5.00%
Eloxx Pharmaceuticals  
Schedule of Equity Method Investments [Line Items]  
Ownership percentage, cost method 3.00%
Xenetic Biosciences, Inc.  
Schedule of Equity Method Investments [Line Items]  
Ownership percentage, equity method 4.00%